NT-proBNP联合galectin-3对慢性心力衰竭患者预后的评估价值

摘要

Objective To evaluate prognostic value of N-terminal B-type brain natriuretic peptide (NT-proBNP) combined with galectin 3 of prognostic value in patients with chronic heart failure (CHF).Methods Determination of 92 cases of CHF patients on admission and at discharge plasma NT-proBNP and galectin-3 levels,then after the patients discharge we follow up 16 months and observe the internal recurrent heart failure hospitalization rate and mortality.Results In patients the heart function of New York Heart Association (NYHA) Ⅰ,Ⅱ,Ⅲ,Ⅳ level,NT-proBNP were (351.6 ± 467.5) pg/ml,(493.2 ± 411.7) pg/ml,(1 289.6 ± 737.8) pg/ml,(2 719.2 ± 1 044.1) pg/ml,galectin-3 (12.23 ± 6.12) ng/ml,(13.59± 5.46) ng/ml,(19.18 ± 7.44) ng/ml,(26.61 ± 8.82) ng/ml as well.NT-proBNP and galectin-3 levels were increased with the depression of cardiac function.The patients who had higher NT-proBNP or galectin3 levels discharged and occurred the more probability of re-hospitalization on account of heart failure or death.Compared to those patients with one of them increased,the patients whose discharge NT-proBNP and galectin-3 value were both increased with significantly poor outcome.Conclusions Both NT-proBNP and galectin-3 were independent predictors of poor prognosis in patients with heart failure.Galectin-3 combined with NT-proBNP can assess the prognosis of patients with CHF more effectively.%目的 评价N端B型脑钠肽前体(NT-proBNP)联合半乳糖凝集素3(galectin-3)对慢性心力衰竭(CHF)患者预后的价值.方法 测定92例CHF患者入院和出院时血NT-proBNP和galectin-3水平,观察、随访出院后16个月内因心力衰竭再发住院率及死亡率.结果 美国纽约心脏病协会(NYHA)心功能Ⅰ、Ⅱ、Ⅲ、Ⅳ级患者NT-proBNP水平分别为(351.6±467.5)pg/ml、(493.2±411.7) pg/ml、(1 289.6±737.8) pg/ml、(2719.2±1 044.1)pg/ml;galectin-3水平分别为(12.23±6.12) ng/ml、(13.59±5.46) ng/ml、(21.18±7.44) ng/ml、(26.61±8.82) ng/mlo NT-proBNP和galec-tin-3的水平随患者心功能的降低而升高.出院时NT-proBNP或galectin-3仍高于正常的患者在随访中发生心力衰竭再发住院或死亡的几率明显高于正常的患者;而出院时NT-proBNP和galectin-3均增高的患者其预后明显较其中一项值增高的患者差.结论 NT-proBNP和galectin-3两者均是心力衰竭患者不良预后的独立预测指标,galectin-3联合NT-proBNP可以更好地评估CHF患者的预后.